Anti-Tau Antibody, clone T49 ZooMAb® Mouse Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone T49 is a ZooMAb® Mouse recombinant monoclonal antibody that specifically detects Tau protein.
• Immunogen: Full-length purified Bovine Tau protein.
• Application: Quality Control TestingEvaluated by Western Blotting in Bovine brain tissue membrane preparations.Western Blotting Analysis: A 1:10,000 dilution of this antibody detected Tau in Bovine brain membrane preparation.Tested ApplicationsImmunohistochemistry (Paraffin) Analysis: A 1:100-1,000 dilution from a representative lot detected Tau in Rat brain, Mouse brain. and Mouse kidney tissue sections.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Tau in Neuro-2a cells.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
• Target description: Microtubule-associated protein tau (UniProt: P29172; also known as Neurofibrillary tangle protein, Paired helical filament-tau, PHF-tau) is encoded by the MAPT (also known as Tau) gene (Gene ID: 281296) in bovine species. Microtubule-associated protein tau that is expressed in neurons  is mostly found in axons, in the cytosol, and in association with plasma membrane components. Twenty isoforms of bovine Tau have been described that are generated by alternative splicing. Tau proteins promote microtubule assembly and stability and may also be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, thus serving as a linker protein between both. The short isoforms are reported to allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. In Alzheimer disease (AD), the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of Tau. In AD brain  Tau undergoes phosphorylation at various serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases and at serine residues in K-X-G-S motifs by MAP and microtubule affinity-regulating kinases (MARK1, MARK2, MARK3, MARK4) that results in detachment from microtubules, and their disassembly. It also undergoes O-glycosylation at least on four GlcNAc and site-specific or stoichiometric changes in glycosylation may modulate tau function and also play a role in PHF′s formation. Tau is shown to accumulate in both the somatodendritic and axonal regions of neurons and in the soma as neurofibrillary tangles (NFTs). Tau oligomers are reported to be neurotoxic when applied extracellularly to cultured neuronal cells and can induce neurodegeneration and synaptic and mitochondrial dysfunction in vivo. It has been reported that most of the C-terminus of Tau in PHFs can be cleaved by trypsin, however the TauC4 region is highly resistant to trypsin action. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Taniguchi Watanabe, S., et al. (2016). Acta Neuropathol. 131(2); 267-280; Ando K., et al. (2010). Biochem. Soc. Trans. 38(4); 1001-1005; Arnold, CS., et al. (1996). J. Biol. Chem. 271(46); 28741-28744).
• Physical form: Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
• Reconstitution: 0.3 mg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.